Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Evolus, Inc. (EOLS) Guidance & Earnings Results

On 2026-08-05 Evolus, Inc. raised guidance: "Net revenue guidance raised to $330-337M from prior; adjusted gross profit margin guidance raised to…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

EOLSEvolus, Inc.Follow EOLS — free
Drug Manufacturers - Specialty & Generic · Healthcare
—
Price chart with a free account
Market cap
463.0M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
5 Aug 26RaisedNet revenue guidance raised to $330-337M from prior; adjusted gross profit margin guidance raised to 67.0-67.5%. · full year
4 May 26ReaffirmedFull-year 2026 net revenue guidance of $327M to $337M; non-GAAP operating expenses $210M to $216M · full year
9 Jan 26RaisedFY2026 revenue $327M-$337M, 11-13% growth
5 Nov 25ReaffirmedFY2025 revenue guidance $295-305M; Q4 2025 non-GAAP operating income $5-7M · full year
5 Aug 25LoweredFY2025 revenue guidance cut to $295-305M from prior; non-GAAP opex rebased to $208-213M; maintains 2028 $700M revenue target and 20% non-GAAP op margin · full year

Evolus, Inc. — questions

What guidance did Evolus, Inc. give?
On 2026-08-05: "Net revenue guidance raised to $330-337M from prior; adjusted gross profit margin guidance raised to 67.0-67.5%."
When does Evolus, Inc. report earnings?
Evolus, Inc.'s next earnings report is expected on 2026-11-04.

Every figure on this page comes from Evolus, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.